Literature DB >> 993645

Removal of heparin and protamine from plasma.

A R Thompson, R B Counts.   

Abstract

A simple chromatographic technique for rapid adsorption of heparin and protamine from plasma samples is described, allowing accurate interpretation of coagulation screening tests and specific clotting factor assays. With the use of columns of ECTEOLA-cellulose, up to 300 U. of heparin could be completely adsorbed from a 1 ml. plasma sample. When citrated nonheparinized plasma was passed over the ECTEOLA-cellulose columns, the thrombin, prothrombin, and partial thromboplastin times were unaffected. Levels of fibrinogen, prothrombin, and factors V, VII, VIII, IX, and XI average within 90 per cent of control, nonchromatographed samples. When heparinized plasma samples (0.1 and 1.0 U. per milliliter) were passed over columns, heparin was completely removed and the results of the screening tests and the specific factor assays were the same as for the chromatographed nonheparinized samples. In addition, heparinized samples with decreased factor VIII activity maintained their pretreatment factor VII activities after heparin removal. Blood samples containing heparin were obtained from two patients during open-heart surgery. Following heparin adsorption on ECTEOLA-cellulose columns, factor VIII activity levels remained above 60 per cent during cardiopulmonary by-pass. The presence of protamine sulfate in plasma samples prolonged the prothrombin and partial thromboplastin times while slightly shortening the thrombin time. The protamine effect persisted after ECTEOLA-cellulose, but could be removed by a similar column of carboxymethyl-cellulose. The latter resin had no effect on screening tests or on assays of factors VIII or IX activity. The combination of the two resins was then used to remove the separate inhibitory effects from heparinized plasma samples to which protamine had been added.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 993645

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  7 in total

1.  Inhibition of the activation of Hageman factor (factor XII) by human vascular endothelial cell culture supernates.

Authors:  O D Ratnoff; B Everson; P Embury; N P Ziats; J M Anderson; M M Emanuelson; C J Malemud
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.

Authors:  Rui-Jun Su; Angela Epp; Yvette Latchman; Doug Bolgiano; Steven W Pipe; Neil C Josephson
Journal:  Mol Ther       Date:  2009-09-15       Impact factor: 11.454

3.  A structured approach to the management of purpura fulminans.

Authors:  H E Branson; J Katz
Journal:  J Natl Med Assoc       Date:  1983-08       Impact factor: 1.798

4.  Screening for nonsense mutations in patients with severe hemophilia A can provide rapid, direct carrier detection.

Authors:  A P Reiner; A R Thompson
Journal:  Hum Genet       Date:  1992-04       Impact factor: 4.132

5.  A practical heparin reduction algorithm: execution and operational characteristics.

Authors:  H E Branson; D van Stralen; J Schottinger; W Peters; Y Endo
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

6.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

7.  Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.

Authors:  A R Thompson
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.